WE CAN HELP
Book a FREE consultation  
For a free consultation or assistance, please call 020 7730 6666

Hair Loss Blog

Browse by Category

Belgravia Centre Hair Loss Treatment Before and After Results - New Success Story

ALERT success story female pattern hair loss treatment belgravia centre 14 11 2018A new entry has just been added to Belgravia’s Women’s Hair Loss Treatment Success Stories gallery.

This client has two separate conditions – Telogen Effluvium, which is temporary, and Female Pattern Hair Loss, which is permanent. These are being treated simultaneously via a customised treatment course tailored to her specific needs by her dedicated hair specialist, and – as you can see – her thinning is showing signs of continuous improvement.

Read her review and see her regrowth results close up in her Success Story, or find out more about treating hair loss in women by clicking the buttons below…

(Results may vary and are not guaranteed)

View succeSS STORY

TELOGEN EFFLUVIUM TREATMENT 

FEMALE HAIR LOSS TREATMENT 

 


The Belgravia Centre

The Belgravia Centre is an organisation specialising in hair growth and hair loss prevention with two clinics and in-house pharmacies in Central London, UK. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the world. View our Hair Loss Success Stories, which includes the world’s largest gallery of hair growth comparison photos and demonstrates the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time to arrange a free consultation.


It’s often the case that miraculous-sounding innovations claiming to cure hair loss announce that they are starting clinical trials, never to be heard of again. This is certainly not the case when it comes to the area of janus kinase (JAK) inhibition.

Diagram Belgravia Centre Different Types of Alopecia Areata autoimmune hair loss

Areas affected by hair loss shown in blue

The many on-going studies that have been investigating how to use this suite of drugs since it was shown they had potential applications for Alopecia Areata hair regrowth, even in the most extensive cases of autoimmune baldness, have all continuously provided timely updates.

The latest of these comes from Concert Pharmaceuticals which announced the initial findings from the first two cohorts of its Phase IIa trial of CTP-543 via press release on 12th November 2018.

Significant differences observed after 12 weeks

Top-line data from the latest Phase IIa stage of the clinical trial into the oral drug CTP-543, as a potential treatment for moderate to severe forms of Alopecia Areata, the autoimmune disorder which causes baldness in hair-bearing areas, from rounded patchy hair loss of the scalp only (Alopecia Areata) to complete baldness of the head and from head to toe in cases of Alopecia Totalis and Alopecia Universalis, respectively.

Whilst there are currently Alopecia Areata treatment options for the scalp-only phenotype, the more extensive forms have limited options with generally low rates of success.

CTP-543 is a modified version of the JAK inhibitor ruxolitinib, and these reports are taken from the findings after 24 weeks of study into 8mg per day doses versus a placebo.

When comparing patients’ baseline hair growth levels (measured just before starting treatment) to those at Week 12 and Week 24, Concert reports that ‘patients treated with an 8mg twice-daily dose of CTP-543 met the primary efficacy endpoint versus placebo (p <0.001). At this dose, significant differences from placebo were observed beginning at Week 12. Regrowth of hair did not appear to plateau at Week 24.’

More results to come

One of the concerns regarding the use of JAK inhibitors as hair loss treatments has centred around potential side effects; whilst some pharmaceutical companies are opting to develop topical versions to help minimise the chance of adverse reactions, Concert notes in this latest release its treatment was ‘generally well tolerated’.

In September 2018 the company advised that it would be also be investigating the effect of 12mg/day doses; this arm of the trial is currently underway and we estimate top-line results will be made available by the end of January 2019.

Concert Pharmaceuticals was the first of three companies the American medical regulatory board, the FDA, granted Fast Track status to, with regards its development of CTP-543. Due to the lack of FDA-approved treatment for Alopecia Areata, Totalis or Universalis, the government body is hoping to assist promising researchers to bring their treatments to market as soon as possible, by prioritising their reviews. It is currently believed that the first JAK inhibitor treatment for severe autoimmune alopecia is likely to be made available for prescription by 2021/22.


Circ - Belgravia Centre Hair Loss Clinics LondonThe Belgravia Centre

The Belgravia Centre is an organisation specialising in hair growth and hair loss prevention with two clinics and in-house pharmacies in Central London, UK. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the world. View our Hair Loss Success Stories, which includes the world’s largest gallery of hair growth comparison photos and demonstrates the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time to arrange a free consultation.


Related Stories


Belgravia Centre Hair Loss Treatment Before and After Results - New Success Story

ALERT Belgravia Centre male pattern hair loss treatment success story 13 11 18 ibA new entry has just been added to Belgravia’s Male Hair Loss Treatment Success Stories gallery.

This happy client left a handwritten review in the guest book of Belgravia’s Central London hair loss clinic, and wanted to thank our “the friendly and encouraging staff”.

You can read his review and also see his hair growth results close up in his Success Story, or find out more about treating Male Pattern Baldness by clicking the buttons below…

(Results may vary and are not guaranteed)

 

VIEW SUCCESS STORY

TreatmenT information 

 


The Belgravia Centre

The Belgravia Centre is an organisation specialising in hair growth and hair loss prevention with two clinics and in-house pharmacies in Central London, UK. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the world. View our Hair Loss Success Stories, which includes the world’s largest gallery of hair growth comparison photos and demonstrates the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time to arrange a free consultation.


HairlossANSWERS - Click to Submit Your Query to Our Hair Loss Experts

Name: Quincy

seborrhoeic dermatitis sebderm itchy flaky scalp

An example of seborrhoeic dermatitis

Question: What is seborrheic hair loss please?

Answer: Hi, Quincy. There is a scalp problem known as seborrhoeic dermatitis but this is a chronic dermatological issue rather than a hair loss condition. In infants it is referred to as cradle cap.

We have heard reference to ‘seborrhoeic hair loss’ or ‘seborrhoeic alopecia’ before but this is something of a misnomer. Seborrhoeic dermatitis – also known as sebderm – causes flaky skin to form in patches that can be greasy, red and itchy, these may also ‘weep’. It can cause flakes of skin in the hair, and, particularly in colder weather, may also lead to dandruff. This issue can also be exacerbated by stress.

Although it is most commonly found on the scalp, sebderm can also affect the face, the ears (inside and behind), and other areas of the body – typically those considered ‘greasy’ (sebaceous) skin zones.

It is linked to an overgrowth of the yeast malassezia on the skin which can lead to inflammation in the affected areas. This is understood to be triggered when the sebaceous glands produce sebum in larger-than-normal quantities.

The only known links between seborrhoeic dermatitis and hair loss revolve around this inflammation sometimes deterring localised hair growth, and repeated scratching of the itchy scalp.

Due to the intense itching sensation it can cause, it is not uncommon for people with sebderm to scratch their scalps to the point where they become bloody from broken skin. This can then cause damage to the hair follicles.

In the majority of cases, where the follicles are still functional and on-going treatment is sought for the effective management of seborrhoeic dermatitis (usually in the form of a medicated shampoo containing ingredients such as zinc pyrithione, selenium sulphide or ketoconazole, or topical steroid solutions), normal hair growth should resume naturally. In extreme cases, where the scalp has become scarred and follicles are no longer able to produce hair, there will be permanent hair loss in these areas.

If you are concerned about hair loss and any scalp conditions you may have, a consultation with a professional hair specialist can be an easy way to get a diagnosis, as well as personalised treatment recommendations, where appropriate, tailored to their findings.


Circ - Belgravia Centre Hair Loss Clinics LondonThe Belgravia Centre

The Belgravia Centre is an organisation specialising in hair growth and hair loss prevention with two clinics and in-house pharmacies in Central London, UK. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the world. View our Hair Loss Success Stories, which includes the world’s largest gallery of hair growth comparison photos and demonstrates the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time to arrange a free consultation.


Related Stories


Belgravia Centre Hair Loss Treatment Before and After Results - New Success Story

alert female pattern hair loss the belgravia centre 08 11 2018A new entry has just been added to Belgravia’s Female Pattern Hair Loss Treatment Success Stories gallery.

This client has seen great improvement to her thinning hair since starting her personalised course.

Find out what she had to say and see her regrowth results close up, or find out more about treating hereditary hair loss in women by clicking the buttons below…

(Results may vary and are not guaranteed)

 

VIEW SUCCESS STORY

TreatmenT information 

 

 


Circ - Belgravia Centre Hair Loss Clinics LondonThe Belgravia Centre

The Belgravia Centre is an organisation specialising in hair growth and hair loss prevention with two clinics and in-house pharmacies in Central London, UK. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the world. View our Hair Loss Success Stories, which includes the world’s largest gallery of hair growth comparison photos and demonstrates the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time to arrange a free consultation.


Hypotrichosis simplex is a progressive, rare form of hair loss which involves the hair shaft becoming increasingly thinner. It tends to start in early childhood and worsen with age.

There are three forms of hypotrichosis simplex; one is confined to causing diffuse hair thinning to the scalp only, whilst another other also affects all body hair. The third form, known as the Marie Unna type, is less seen and involves a twisting hair dystrophy.

The appearance of thinning hair in these instances is similar to that found in cases of genetic hair loss – Male Pattern Baldness and Female Pattern Hair Loss – and is also hereditary, so genetics are still very much involved.

Example of hypotrichosis simplex hair lossTo this end, according to research published in the American Journal of Human Genetics, a new gene responsible for hypotrichosis simplex has been discovered by researchers in Germany.

Enzyme impairment

Prof. Dr. Regina C. Betz  from the team of German and Swiss researchers at the University Hospital of Bonn’s Institute of Human Genetics, which has been investigating the cause of hypotrichosis simplex by studying affected families, explained the new gene development.

This gene encodes lanosterol synthase — LSS for short. The enzyme plays a key role in cholesterol metabolism. There is an alternative metabolic pathway for cholesterol, which plays an important role in the hair follicle and is not related to blood cholesterol levels.

Cholesterol blood values remain unaffected by this in those with the condition.

“We are not yet able to say why the hair is falling out,” lead study author Maria-Teresa Romano, a doctoral student in Prof. Betz’s team, told Science Daily. “It is likely that the displacement of LSS from the endoplasmic reticulum results in a malfunction.”

Previously, according to information from the US Department of Health & Human Services’ Genetic and Rare Diseases Information Centre, hypotrichosis simplex was only thought to occur as a result of inheriting it as either an autosomal dominant or autosomal recessive trait, or where there are mutations in the APCDD1 gene on chromosome 18p11.

Help understanding of pattern hair loss

The University Hospital of Bonn team states that relatively little is known about controlling hair growth on a molecular level, but is optimistic that this new discovery will benefit not only those investigating hypotrichosis simplex, but also genetic hair loss, as well as potentially furthering our understanding of hair growth in general.

The team’s findings state: ‘Investigation of genetic conditions in individuals with isolated alopecia offers the unique possibility to identify factors that are not only necessary but also specific for hair growth. HSS [hypotrichosis simplex], with no involvement of body hair, eyebrows, and eyelashes, may be particularly important for our understanding of the genetic, molecular, and cellular pathways that regulate growth of scalp hair. Interestingly, the histological picture of scalp biopsies from patients with HSS has many features of androgenetic alopecia, such as miniaturized follicles of the vellus type and absence of scarring (Ibsen et al. 1991). Ultimately, the identification of the mutated gene could illuminate our understanding of common androgenetic alopecia.’

Although there are clinically-proven, MHRA licensed and FDA approved hair loss treatments for male and female pattern baldness, there are currently no options for treating hypotrichosis simplex. However, with every new development – like this latest gene discovery – scientists get closer to understanding how one may be developed.


The Belgravia Centre

The Belgravia Centre is an organisation specialising in hair growth and hair loss prevention with two clinics and in-house pharmacies in Central London, UK. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the world. View our Hair Loss Success Stories, which includes the world’s largest gallery of hair growth comparison photos and demonstrates the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time to arrange a free consultation.


Related Stories


Belgravia Centre Hair Loss Treatment Before and After Results - New Success Story

alert female pattern hair loss the belgravia centre 07 11 2018A new entry has just been added to Belgravia’s Female Pattern Hair Loss Treatment Success Stories gallery.

Zara, pictured, has seen an improvement to the density of her hair since starting treatment saying “in three months the difference was amazing!”

Find out what else she had to say and see her regrowth results close up, or find out more about treating hereditary hair loss in women by clicking the buttons below…

(Results may vary and are not guaranteed)

 

VIEW SUCCESS STORY

TreatmenT information 

 


Circ - Belgravia Centre Hair Loss Clinics LondonThe Belgravia Centre

The Belgravia Centre is an organisation specialising in hair growth and hair loss prevention with two clinics and in-house pharmacies in Central London, UK. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the world. View our Hair Loss Success Stories, which includes the world’s largest gallery of hair growth comparison photos and demonstrates the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time to arrange a free consultation.


HairlossANSWERS - Click to Submit Your Query to Our Hair Loss Experts

Name: Jenny

Shampoo shower hair wash advice waterQuestion: I read online that using cold water at the end of washing your hair made your hair shinier, but today I read something that said using cold water could contract the blood vessels in your scalp and negatively affect hair growth. What do you think about using cold water at the end of a hair wash? Does it affect hair growth?

Answer: Hi, Jenny. Thank you for checking this with us as there are many hair myths and lots of information about hair growth online that comes from non-professional sources and is not necessarily true.

Cold water doesn’t close the cuticles. When the hair is wet, the cuticle layer will be open regardless of the temperature. However, some people believe that cold water lifts the cuticle scales less than hot water.  Either way, once the hair dries, the cuticle scales will close.

If the hair is porous, cuticle scales may be missing and the hair can look dry, dull and frizzy, regardless what water temperature is used to rinse the hair. In healthy hair cuticle scales close smoothly and, as the hair reflects light, it will appear shiny.

Whilst Afro textured hair is the most likely to be porous, any hair type can be porous though Asian hair is the least likely to be affected. Over-processing with chemicals or heat is the biggest contributor to hair porosity, regardless of hair type. You can tell if your hair is porous or not by taking a strand between your thumb and index finger, then sliding your fingers along it from root to end. The hair should feels smooth; if it feels rough, there may be swelling of the cortex or longitudinal splitting of the hair shaft or any other form of damage. This would mean the hair is porous.

Straight hair tends to look shinier than curly hair because of the way it reflects light, but it doesn’t necessarily mean that it is healthier. It is simply because curls cause shadows and curly hair therefore has a naturally less shiny appearance.

Some people like to alternate hot and cold water in the shower as they believe this will increase the blood circulation. Also, some like finishing a shower with cold water as it will constrict the pores of the skin making it appear clearer. In terms of hair growth, this wouldn’t have a significant effect either way.

I would say, with regards to how shiny the hair is or can be, this depends on the health of the hair and the products used on the hair, rather than the water temperature used when rinsing.


The Belgravia Centre

The Belgravia Centre is an organisation specialising in hair growth and hair loss prevention with two clinics and in-house pharmacies in Central London, UK. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the world. View our Hair Loss Success Stories, which includes the world’s largest gallery of hair growth comparison photos and demonstrates the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time to arrange a free consultation.


Related Stories


Belgravia Centre Hair Loss Treatment Before and After Results - New Success Story

alert male pattern hair loss the belgravia centre 05 11 2018A new entry has just been added to Belgravia’s Male Hair Loss Treatment Success Stories gallery.

James, pictured, is feeling good since starting treatment saying it’s a “Huge confidence booster.”

Find out what else he had to say and see his regrowth results close up, or find out more about treating Male Pattern Baldness by clicking the buttons below…

(Results may vary and are not guaranteed)

 

VIEW SUCCESS STORY

TreatmenT information 

 


Circ - Male Pattern Baldness hair loss treatment Belgravia Centre clinic LondonThe Belgravia Centre

The Belgravia Centre is an organisation specialising in hair growth and hair loss prevention with two clinics and in-house pharmacies in Central London, UK. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the world. View our Hair Loss Success Stories, which includes the world’s largest gallery of hair growth comparison photos and demonstrates the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time to arrange a free consultation.


Regular readers of Belgravia’s blog will know that the area of JAK inhibition has been consistently looking like the most feasible source for the first ever FDA approved treatments for even the most severe forms of Alopecia Areata.

Alopecia Areata has three main phenotypes – Alopecia Areata, which causes patchy hair loss to the scalp only and generally clears up within a year, Alopecia Totalis which leads to baldness of the head, including scalp and facial hair, and Alopecia Universalis – the most extensive iteration which presents as baldness from head to toe. These are autoimmune diseases which disrupt the hair growth cycle and cause the body to attack its hair follicles to varying degrees in a range of hair-bearing areas.

As we inch closer to the estimated release date of 2021/22, more players are jockeying for pole position in this race to address a currently unmet need.

To this end Incyte Corporation has recently updated the clinical trial registration documentation regarding its Phase 2 and Phase 3 trials for the oral JAK inhibitor, baricitinib. The baricitinib formulation is known by the code LY3009104.

medication-pills-capsules-health-illnessAddressing an unmet need

Over the past few years researchers, particularly those at Columbia University’s medical school in New York, and pharmaceutical companies from Aclaris Therapeutics to Pfizer, have been pulling out all the stops to develop safe, tolerable and effective hair loss solutions from established JAK inhibitor drugs.

Whilst Pfizer’s work in this area has received a Breakthrough Therapy designation from the FDA, both Aclaris Therapeutics and Concert Pharmaceuticals have been granted Fast Track status for their janus kinase (JAK) inhibitor-based formulations. The focus on bringing the most suitable treatments to market as soon as possible is due to the FDA wanting to establish a viable, safe and clinically-proven treatment for these conditions which currently have limited options yet can cause extreme distress to those affected.

Announced in August 2018, Incyte’s wide-ranging interventional, double blind trial started on 24th September 2018, and is taking place at a number of locations across the USA, Japan and Puerto Rico. It involves 725 participants taking one of three pills – high dose baricitinib, low dose baricitinib or a placebo. Their scalp hair growth, eyelash and eyebrow hair changes will be assessed at week 1 and week 36 of the trial.

Trialled on adult participants

All the volunteers are aged 18 to 70 years with confirmed Alopecia Totalis or Alopecia Universalis; those with the more mild to moderate scalp-only phenotype are excluded from the study.

Whilst there are no products currently approved by the FDA or MHRA licensed for the purpose of treating Alopecia Areata, there are clinically-proven medications which have been recognised by both for the treatment of genetic hair loss in both men and women. Hair loss specialists have found that when the topical solutions are consistently applied to the scalp where needed, as directed, they can have a significant effect on the scalp-only form.

Baricitinib is the active ingredient in the existing Incyte drug, Olumiant, designed for the treatment of rheumatoid arthritis – another autoimmune disorder. The 2mg dose of this medication was FDA approved for this purpose only in April 2018 though a higher dose was rejected on the grounds of concerns regarding side effects. This factor has previously been raised in connection with other JAK inhibitors being redeveloped as potential autoimmune hair loss treatments, particularly tofacitinib. It is thought to be the reason other companies are also exploring topical JAK inhibitors, as this delivery method can often help to minimise adverse reactions.

As more information regarding the race to produce the first JAK inhibitor alopecia areata treatment becomes available, we will publish it on the Alopecia section of Belgravia’s hair loss blog, and are cautiously optimistic that everything seems on track with regards the initial estimated release date.

In the meantime, adults concerned about sudden hair fall and bald patches appearing can take advice from a hair loss specialist where their scalp is the only area affected; children under 16 with any form of alopecia and adults with the more extensive phenotypes should consult their GP or dermatologist first, for advice and information.


Circ - Belgravia Centre Hair Loss Clinics LondonThe Belgravia Centre

The Belgravia Centre is an organisation specialising in hair growth and hair loss prevention with two clinics and in-house pharmacies in Central London, UK. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the world. View our Hair Loss Success Stories, which includes the world’s largest gallery of hair growth comparison photos and demonstrates the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time to arrange a free consultation.


Related Stories